CD34 and chronic kidney disease: Recently, Huang et al. demonstrated that PB-CD34+ EPC therapy excellently inhibits CKD progression and kidney homeostasis deterioration by means of improvement of neoangiogenesis, blood stream, and potent anti-oxidative, anti-inflammatory, and anti-apoptosis/fibrosis capacities in a rat model (Huang et al., 2015).